Could daratumumab be used to treat severe allergy?

Journal of Allergy and Clinical Immunology

Volumn 139, Issue 5, 2017, Pages 1677-1678.e3

  Blankestijn, Mark A ^a   van de Donk, Niels W C J ^b   Sasser, Kate ^c   Knulst, André C ^a   Otten, Henny G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DARATUMUMAB; DEXAMETHASONE; IMMUNOGLOBULIN E; LENALIDOMIDE; OMALIZUMAB; ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; HOUSE DUST ALLERGEN; MONOCLONAL ANTIBODY;

ALLERGIC ASTHMA; ARTICLE; ASTHMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DERMATOPHAGOIDES; DISEASE SEVERITY; FOOD ALLERGY; FOOD AND DRUG ADMINISTRATION; GRASS POLLEN; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; MONOTHERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RHINITIS; TREATMENT OUTCOME; ANIMAL; BIRCH; BLOOD; DRUG APPROVAL; DRUG EFFECT; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; NETHERLANDS; PLASMA CELL; POLLEN; PROCEDURES; PYROGLYPHIDAE;

ADP-RIBOSYL CYCLASE 1; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DERMATOPHAGOIDES; BETULA; DRUG APPROVAL; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MULTIPLE MYELOMA; NETHERLANDS; PLASMA CELLS; POLLEN; PYROGLYPHIDAE;

EID: 85012908677     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.12.955     Document Type: Article

References (9)

1. 1 Baena-Cagnani, C.E., Gómez, R.M., Current status of therapy with omalizumab in children. Curr Opin Allergy Clin Immunol 14 (2014), 149–154.
2. 2 Dasgupta, A., Radford, K., Arnold, D.M., Thabane, L., Nair, P., The effects of rituximab on serum IgE and BAFF. Allergy Asthma Clin Immunol, 9, 2013, 39.
3. 3 Rosenberg, A.S., Pariser, A.R., Diamond, B., Yao, L., Turka, L.A., Lacana, E., et al. A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins. Clin Immunol 165 (2016), 55–59.
4. 4 Wegmann, M., Lunding, L., Orinska, Z., Wong, D.M., Manz, R.A., Fehrenbach, H., Long-term bortezomib treatment reduces allergen-specific IgE but fails to ameliorate chronic asthma in mice. Int Arch Allergy Immunol 158 (2012), 43–53.
5. 5 Lokhorst, H.M., Plesner, T., Laubach, J.P., Nahi, H., Gimsing, P., Hansson, M., et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373 (2015), 1207–1219.
6. 6 Plesner, T., Arkenau, H.-T., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M.C., et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. [published online ahead of print August 16, 2016] Blood 128 (2016), 1821–1828.
7. 7 Lapalombella, R., Andritsos, L., Liu, Q., May, S.E., Browning, R., Pham, L.V., et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 115 (2010), 2619–2629.
8. 8 Strati, P., Keating, M.J., Wierda, W.G., Badoux, X.C., Calin, S., Reuben, J.M., et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122 (2013), 734–737.
9. 9 Wu, C.Y., Sarfati, M., Heusser, C., Fournier, S., Rubio-Trujillo, M., Peleman, R., et al. Glucocorticoids increase the synthesis of immunoglobulin E by interleukin 4-stimulated human lymphocytes. J Clin Invest 87 (1991), 870–877.